| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| NVS | Novartis AG | $85.13 | $197.65B | N/A |
Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
http://www.zacks.com/stock/news/430687/novartis-nvs-announces-promising-data-on-tasigna-hyrimoz?cid=CS-ZC-FT-430687
Jun 17, 2019 - Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.
0
Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris
http://www.zacks.com/stock/news/429338/roche-reports-positive-data-on-rituxan-for-pemphigus-vulgaris?cid=CS-ZC-FT-429338
Jun 13, 2019 - Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.
0
Top Analyst Reports for Visa, Netflix & Accenture
http://www.zacks.com/research-daily/429094/top-analyst-reports-for-visa-netflix-accenture?cid=CS-ZC-FT-429094
Jun 13, 2019 - Top Analyst Reports for Visa, Netflix & Accenture
0
Elastic Nv (ESTC) CEO and Chairman Shay Banon Sold $15.9 million of Shares
http://www.gurufocus.com/news/893420/elastic-nv-estc-ceo-and-chairman-shay-banon-sold-159-million-of-shares
Jun 12, 2019 - Elastic Nv (ESTC) CEO and Chairman Shay Banon Sold $15.9 million of Shares, Stocks: ESTC, release date:Jun 12, 2019
0
Roche's Rituxan Gets Priority Review for Blood Disorder
http://www.zacks.com/stock/news/428757/roches-rituxan-gets-priority-review-for-blood-disorder?cid=CS-ZC-FT-428757
Jun 12, 2019 - Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.
0
Novartis Reports Data on Cosentyx for Psoriatic Arthritis
http://www.zacks.com/stock/news/428752/novartis-reports-data-on-cosentyx-for-psoriatic-arthritis?cid=CS-ZC-FT-428752
Jun 12, 2019 - Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.
0
Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug
http://www.zacks.com/stock/news/427399/dr-reddys-reports-positive-top-line-data-on-psoriasis-drug?cid=CS-ZC-FT-427399
Jun 10, 2019 - Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
0
Roche Receives FTC Request for Further Data on Spark Buyout
http://www.zacks.com/stock/news/427145/roche-receives-ftc-request-for-further-data-on-spark-buyout?cid=CS-ZC-FT-427145
Jun 10, 2019 - Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.
0
Celgene's Filing for Ozanimod Accepted for Review in US/EU
http://www.zacks.com/stock/news/426482/celgenes-filing-for-ozanimod-accepted-for-review-in-us-eu?cid=CS-ZC-FT-426482
Jun 07, 2019 - The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.
0
Is Aegon NV (AEG) a Suitable Stock for Value Investors Now?
http://www.zacks.com/stock/news/426167/is-aegon-nv-aeg-a-suitable-stock-for-value-investors-now?cid=CS-ZC-FT-426167
Jun 07, 2019 - Let's see if Aegon NV (AEG) stock is a good choice for value-oriented investors right now from multiple angles.
0
Page 1>